Open AccessComparison of moxalactam (LY127935) and cefotaxime against anaerobic bacteria
Author(s) -
J. H. Jorgensen,
S. A. Crawford,
G A Alexander
Publication year - 1980
Publication title -
antimicrobial agents and chemotherapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.07
H-Index - 259
eISSN - 1070-6283
pISSN - 0066-4804
DOI - 10.1128/aac.17.5.901
Subject(s) - moxalactam , bacteroides fragilis , microbiology and biotechnology , cefoxitin , cefotaxime , cefamandole , carbenicillin , anaerobic bacteria , penicillin , eubacterium , cefuroxime , fusobacterium , actinomyces , bacteroides , antibiotics , biology , bacteria , cephalosporin , ampicillin , genetics , staphylococcus aureus
The in vitro activities of moxalactam (LY127935 [6059S]) and cefotaxime were compared with those of cefoxitin, cefamandole, cefuroxime, carbenicillin, and penicillin by agar dilution susceptibility testing of a variety of anaerobic bacteria. Moxalactam proved to be the most active agent tested against Bacteroides fragilis and other species of the B. fragilis group. Moxalactam and cefotaxime showed activity similar to the other drugs against the remaining species of Bacteroides, Fusobacterium, Actinomyces, Propionibacterium, and Veillonella. Penicillin was the most effective drug tested against most species of Clostridium, the anaerobic gram-positive cocci, and Eubacterium lentum.